Roam Analytics is a technology company.
Roam Analytics has raised $12.0M across 2 funding rounds.
Roam Analytics has raised $12.0M in total across 2 funding rounds.
Roam Analytics has raised $12.0M in total across 2 funding rounds.
Roam Analytics's investors include 9Yards Capital, Kevin Hartz, Accel, Acrew Capital, Adverb Ventures, AME Cloud Ventures, Audrey Capital, Benchstrength, Blitzscaling Ventures, Bond, Broadway Angels, C2 Investment.
Roam Analytics is a technology company that builds an AI-powered platform to analyze unstructured language data from healthcare records, transforming it into structured insights for pharmaceutical companies, medical device manufacturers, and healthcare providers.[1][2][3] It serves healthcare organizations by solving the problem of inaccessible textual data in electronic medical records, enabling predictive modeling, patient population analysis, and better treatment decisions through natural language processing (NLP) and deep learning.[2][3] The company's mission is to "leverage artificial intelligence to improve human health" by empowering healthcare companies to derive structured meaning from language data.[1][4][5]
Founded in 2013 and headquartered in San Mateo, California, Roam Analytics grew its platform to handle 1 billion edges by June 2018, supporting applications like HIV outcome prediction and private knowledge graphs for drugs, symptoms, and diseases.[2] It demonstrated early traction through partnerships, such as with ViiV Healthcare, and research presented at the AIDS 2018 conference.[2]
Roam Analytics was co-founded in 2013 by Alex Turkeltaub, Andrew Maas, and Atul Suklikar (with some sources emphasizing Turkeltaub and Maas).[1][2][3] Turkeltaub, previously co-founder and CEO of Frontier Strategy Group, brought business expertise, while Maas holds a Ph.D. in Computer Science from Stanford University, specializing in deep learning and NLP.[2][3] The idea emerged from the need to unlock unstructured language data in healthcare systems, where electronic records often lack the depth for effective analysis despite vast clinical information.[3]
Early traction included building language processing models for healthcare datasets, research on anonymized patient data (e.g., HIV outcomes with ViiV Healthcare, presented at AIDS 2018), and hosting the inaugural LIGHT conference in 2017 at Stanford with Knight-Hennessy Scholars to explore AI and big data in health.[2] Backed by investors like Sway Ventures and advisors from industry and academia, the company evolved toward predictive analytics and knowledge graphs.[2][3]
Roam Analytics rides the wave of AI-driven healthcare analytics, particularly NLP to tackle the explosion of unstructured data (e.g., clinical notes) amid electronic health record adoption.[3] Timing aligns with post-2010s AI advancements in deep learning, enabling scalable language quantification when healthcare systems struggled with data silos.[2][3] Market forces like rising demand for real-world evidence, personalized medicine, and faster regulatory approvals favor its tools, influencing pharma R&D and patient care ecosystems.[3]
By providing actionable insights from language data, Roam shaped early AI-health intersections, evidenced by partnerships and conferences that bridged tech and medicine; its 2020 acquisition by Parexel integrated these capabilities into global clinical research, amplifying impact on drug development and outcomes analysis.[5]
Post-acquisition by Parexel in 2020, Roam Analytics' NLP tech likely enhances clinical trial analytics and real-world data processing within a larger CRO powerhouse.[5] Next steps could involve scaling to generative AI for even richer insights from multimodal health data, amid trends like federated learning for privacy and AI regulations favoring explainable models. Its influence may evolve from standalone innovator to embedded leader in evidence-based healthcare, powering faster therapies as data volumes grow—echoing its founding mission to quantify language for universal health gains.[1][4][5]
Roam Analytics has raised $12.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in June 2015.